76
|
Kida S, Ichiji M, Watanabe J, Hirasawa I. Particle size distribution and shape control of Au nanoparticles used for particle gun. Front Chem Sci Eng 2013. [DOI: 10.1007/s11705-013-1313-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
77
|
Sato N, Yamamoto D, Rai Y, Iwase H, Saito M, Iwata H, Masuda N, Oura S, Watanabe J, Kuroi K. Abstract P1-12-01: Evaluation on efficacy and safety of capecitabine plus docetaxel versus docetaxel monotherapy in metastatic breast cancer patients pretreated with anthracycline: Results from a randomized phase III study (JO21095). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-12-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: A previous large-scale phase III study demonstrated that, compared with docetaxel (T) alone, capecitabine (X) and T in combination (XT) offered significantly superior progression free survival (PFS) and overall survival (OS) in metastatic breast cancer (MBC). However, XT increased Grade 3/4 adverse events (AEs) which led to more frequent dose reductions than with T alone. Optimal dose of XT in Japanese was examined in a phase Ib study. Based on the background, we conducted a phase III randomized study in Japanese HER2 negative MBC patients pre-treated with anthracycline to compare efficacy and safety of XT therapy and T therapy.
Methods: Eligible pts were HER2-negative MBC pts with anthracycline-pretreatment, a measurable tumor, and ECOG performance status of 0 or 1. Pts were randomly assigned to the XT group or the T→X group. The XT group received concurrent therapy of X (1650 mg/m2/day from day 1 to 14) and T (60 mg/m2) in 3-week cycle. The T→X group received sequential therapy of T (70 mg/m2) in 3-week cycle followed at disease progression by X (2500 mg/m2/day from day 1 to 14 followed by 1-week rest). Primary endpoint was PFS. Secondary endpoints were OS, overall response rate (ORR), time to treatment failure (TTF), safety, and quality of life. The XT group and the T phase of the T→X group (T group) were compared in our evaluation.
Results: Of 163 pts enrolled, 156 were eligible. Baseline characteristics of all pts in each group were well balanced. The median delivered dose was 79.0% and 95.1% of the planned dose respectively for X and T in the XT group, and it was 97.2% in the T group. Median PFS in the XT group was 10.5 months compared to 9.8 months in the T group (hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.40–0.97). The ORR was 70% and 61%; the median TTF was 9.6 months and 7.0 months in the XT group and the T group, respectively. Median OS has not been reached yet. Subgroup analysis showed PFS was longer in pts with liver metastasis (HR, 0.39; 95% CI, 0.19–0.84) and in pts with lung metastasis (HR, 0.43; 95% CI, 0.21–0.90) in the XT group. Incidence of treatment related AEs (TR-AEs) ≥Grade 3 was 74.4% (61 pts) in the XT group and 76.3% (61 pts) in the T group. Frequently reported TR-AEs ≥Grade 3 were; decrease in neutrophil count (XT, 57.3%; T, 60.0%), neutropenia (XT, 8.5%; T, 12.5%) and febrile neutropenia (XT, 6.1%; T, 10.0%). TR-AE ≥Grade 3 in the XT group with incidence at least 5% higher than the T group was hand-foot syndrome (XT, 7.3%; T, 0%). On the other hand, TR-AEs ≥Grade 3 in the T group with incidence at least 5% higher than the XT group were fatigue (XT, 2.4%; T, 8.8%) and peripheral edema (XT, 1.2%; T, 6.3%).
Conclusion: The concurrent therapy of XT demonstrated significant improvement of PFS compared with T alone. Superior efficacy of XT therapy was reported as same as the previously reported study on XT versus T although the dose was lower in our study. Considering the efficacy and tolerability, we consider concurrent Japanease dose XT therapy is a preferable treatment for MBC pts with liver or lung metastasis.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-12-01.
Collapse
|
78
|
Masuda N, Yamamoto D, Sato N, Sagara Y, Yamamoto Y, Saito M, Iwata H, Oura S, Watanabe J, Kuroi K. Abstract P6-07-16: Evaluation of circulating tumor cell as a marker of prognosis and efficacy in a randomized phase III study in HER2 negative metastatic breast cancer patients treated with capecitabine and docetaxel: JO21095 study. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-07-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Circulating tumor cell (CTC) has been reported as a predictive marker of prognosis and treatment response in metastatic breast cancer by comparing CTC count prior to and after treatment. However, most of previous reports were based on retrospective studies and still controversial. We prospectively evaluated CTC as a marker of prognosis and treatment efficacy in a randomized multi-center phase III study in HER2 negative metastatic breast cancer patients (pts) in Japan.
Methods: Pts were randomized into two groups to receive either the concurrent therapy of capecitabine plus docetaxel in 3-week cycle (XT group) or the sequential therapy of docetaxel followed by capecitabine at progression of disease in 3-week cycle (T→X group). Primary endpoint was progression free survival (PFS). Secondary endpoints were overall survival (OS), overall response rate (ORR) and safety. The number of CTC in 7.5 mL of blood sample was measured at the time of screening, after cycle 1, after cycle 2 and at progression of disease (PD) in both groups. Measurement of CTC was conducted by CellSearch System of Veridex. Our evaluation on CTC count was conducted in the XT group and the docetaxel phase of the T→X group.
Results: Of the total 163 pts enrolled in the study, CTC count was evaluated in 158 pts. The number of pts with <2 CTCs was 88 (55.7%) and ≥2 CTCs were 70 (44.3%) at screening. The CTC count was higher in patients with liver or bone metastasis. In pts with ≥2 CTCs, liver metastasis was reported in 47 pts (64%) and bone metastasis in 53 pts (64%) while metastases were less in pts with <2 CTCs. Between the XT group and the docetaxel phase of the T→X group, the median PFS was 10.5 months and 9.8 months (hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.40–0.97) and ORR was 70% and 61%. Analysis of the OS data is under examination. Subgroup analysis showed PFS was longer in pts with liver metastasis (HR = 0.39; 95% CI = 0.19–0.84) or lung metastasis (HR = 0.43; 95% CI, 0.21–0.90) in the XT group. As a result of our exploratory analysis on CTC count, the median PFS was 10.7 months in pts with <2 CTCs and 8.2 months in pts with ≥2 CTCs (HR, 0.65; 95% CI, 0.42–0.99) at screening. The median PFS of pts with ≥2 CTCs at screening and decreased to <2 CTCs after receiving one cycle of study treatment was 8.3 months and that of pts remained ≥2 CTCs was 8.2 months (HR, 0.79; 95% CI, 0.43–1.46). Between the XT group and the T→X group, the respective median PFS was 10.7 months and 12.1 months (HR, 0.83; 95% CI, 0.46–1.49) in pts with <2 CTCs while it was 10.4 months and 7.1 months in patients with ≥2 CTCs (HR, 0.53; 95% CI, 0.28–0.99). No major safety issues of concern were reported.
Conclusion: Results from our study suggested the CTC count at screening could serve as a marker of prognosis and during treatment as a marker of treatment efficacy. The median PFS in the XT group was longer than the T→X group in pts with liver metastasis or ≥2 CTCs. Aggressive treatment with the concurrent therapy of capecitabine and docetaxel could be a preferable treatment option for HER2 negative metastatic breast cancer patients with ≥2 CTCs in the future.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-07-16.
Collapse
|
79
|
Kurata T, Murakami H, Fujisaka Y, Kiyota H, Hayashi H, Tanaka K, Nakagawa K, Onozawa Y, Watanabe J, Yamamoto N, Aoyama T. Phase I Study of Ombrabulin, a Vascular Disrupting Agent (VDA), Administered Every 3 Weeks to Japanese Patients with Advanced Solid Tumors. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32295-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
80
|
Azemoto N, Kumagi T, Yokota T, Kuroda T, Koizumi M, Yamanishi H, Soga Y, Furukawa S, Abe M, Ikeda Y, Hiasa Y, Matsuura B, Watanabe J, Kushihata F, Onji M. An unusual case of subclinical diffuse glucagonoma coexisting with two nodules in the pancreas: characteristic features on computed tomography. Clin Res Hepatol Gastroenterol 2012; 36:e43-7. [PMID: 22239827 DOI: 10.1016/j.clinre.2011.12.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2011] [Revised: 12/02/2011] [Accepted: 12/05/2011] [Indexed: 02/04/2023]
Abstract
A lesion was discovered in the tail of the pancreas by ultrasonography performed during a health checkup for a 59-year-old Japanese man. Abdominal contrast-enhanced computed tomography (CE-CT) revealed strong enhancement in a 4-cm tumor in the pancreatic tail and in a 1-cm tumor in the pancreatic body. Serum glucagon levels were elevated to 54,405 pg/mL and a preoperative diagnosis of glucagonoma was made. The pancreatic tail and spleen were resected en bloc, along with a protruding tumor in the pancreatic body. However, histopathological evaluation revealed diffuse glucagonoma throughout the pancreas. When we retrospectively reviewed abdominal CE-CT after the operation, the entire pancreas was seen to be enlarged and diffusely enhanced by strong spots. Immunohistochemical examination using anti-CD31 demonstrated rich microvessels in two solid glucagonomas as well as microglucagonoma throughout the entire pancreas, indicating hypervascularity. Enlarged pancreas and diffuse enhancement of the pancreas by strong spots may be characteristic features of diffuse glucagonoma on abdominal CE-CT.
Collapse
|
81
|
Watanabe J, Kubo Y, Ogiya A, Tadokoro Y, Tanaka K, Nishikawa N, Sato M, Takahashi K. 236 Bone Management by Bisphosphonate in Metastatic Breast Cancer Patients. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70304-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
82
|
Yamagishi J, Watanabe J, Goo YK, Masatani T, Suzuki Y, Xuan X. Characterization of Toxoplasma gondii 5' UTR with encyclopedic TSS information. J Parasitol 2011; 98:445-7. [PMID: 22010783 DOI: 10.1645/ge-2864.1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
The 5' UTR is widely involved in gene expression via post-transcriptional regulation. However, a detailed profile of the 5' UTR for Toxoplasma gondii has not yet been demonstrated. To investigate the issue, we compared the predicted open reading frames (ORFs) and transcription start sites (TSSs) of T. gondii obtained by TSS-seq, a method that enables analysis of encyclopedic TSSs with next-generation sequencers. As a result, it was demonstrated that the mode length of the 5' UTR is between 120 and 140 nucleotides (nts) when a subset of genes with predicted signal peptides was examined. However, when genes without the signal peptide were examined, the length was extended to approximately 600 nts. Because additional information on the predicted signal peptide generates increased reliability to the 5' end estimation of each ORF, we believe that the former value was more reliable as a representative of the 5' UTR length of T. gondii. The discrepancy suggests that current predictions of the 5' end of the ORF were less accurate and considerably more discordant with the natural status. The 5' untranslated region (5' UTR) is defined as that between the 5' end of the transcripts and just in front of a start codon of an ORF. Therefore, the 5' UTR does not contain any information for a protein sequence; however, it is involved in the control of protein expression via the modulation of translational efficiency (Kozak, 1991b; Hughes, 2006).
Collapse
|
83
|
Onozawa Y, Fujisaka Y, Yasui H, Kurata T, Yamazaki K, Goto I, Machida N, Watanabe J, Shi X, Boku N. 1252 POSTER First Report of the Safety, Tolerability, and Pharmacokinetics of Saracatinib (AZD0530) in Japanese Patients With Advanced Solid Tumours. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70864-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
84
|
Tadokoro Y, Nishikawa N, Ogiya A, Tanaka K, Takahashi K, Mitsuya K, Watanabe J, Yamasaki S, Uematsu T, Kasami M. Breast cancer leptomeningeal metastasis. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
85
|
Watanabe J, Hamauchi S, Higashi Y, Onozawa Y. Lapatinib plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
86
|
Mikami T, Takayasu Y, Watanabe J, Hirasawa I. Influence of Polyethyleneimine Addition on Crystal Size Distribution of Au Nanocrystals. Chem Eng Technol 2011. [DOI: 10.1002/ceat.201000495] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
87
|
Watanabe J, Takahashi K, Tanaka K, Tadokoro Y, Ogiya A, Uematsu T, Kimura M. Abstract P6-11-13: Phase I Study of Combined S-1 Plus Weekly Paclitaxel Therapy in Patients with Metastatic Breast Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p6-11-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: S-1, a novel anticancer compound, contains tegafur, a prodrug of fluorouracil (FU), 5-chloro-2.4-dihydroxypyridine, which prevents FU degradation, and potassium oxonate, which prevents drug-induced diarrhea, has a broad spectrum of activity against gastric, colorectal, head & neck, and breast cancers. While combined S-1 with cisplatin or paclitaxel (PAC) therapy is feasible and highly active against gastrointestinal cancer, the feasibility in breast cancer patients has not yet been clarified. We conducted a phase I study of combined S-1 plus weekly PAC therapy (S-1/PAC) to determine the maximum tolerated dose (MTD), recommended dose (RD) and dose-limiting toxicities (DLT) in patients (pts) with HER2-negative, taxane-naïve metastatic breast cancer (MBC).
Methods: S-1 was administered orally from day 1 through day 14 and PAC was administered intravenously on days 1, 8 and 15 of each 28-day cycle. Since S-1 is prescribed at the dose of 80mg/m2 in monotherapy, the primary dose levels (level 1) were set at 65 and 70mg/m2, respectively. The final dose (level 3) was set at 80mg/m2 for each drugs. DLT was defined over 2 cycles.
Results: Ten MBC pts were enrolled in the study. No DLTs were documented. Although grade 1 or 2 adverse events were seen in all pts, no cases of febrile neutropenia or Gr 4 neutropenia were observed. Of the 8 evaluable pts, 3 pts achieved partial response and 4 pts had stable disease.
Conclusion: Based on the results of this study, RD was determined to be 80mg/m2 for either drugs. We conclude that S-1/PAC was well-tolerated and highly active against HER2-negative MBC.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-11-13.
Collapse
|
88
|
Watanabe J, Horiguchi J, Masuda N, Aogi K, Sato R, Tokudome T, Peck RA. Phase I study of ixabepilone in combination with capecitabine in Japanese patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
89
|
Terao M, Watanabe J, Yagi A, Nishida S. Improvement of chromatic temporal resolution during smooth pursuit eye movement. J Vis 2010. [DOI: 10.1167/8.6.663] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
90
|
Nishida S, Terao M, Watanabe J. Trajectory Integration of Shape and Color of Moving Object. J Vis 2010. [DOI: 10.1167/9.8.21] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
91
|
Terao M, Watanabe J, Yagi A, Nishida S. Flash visibility degradation compresses apparentbrief inter-flash intervals as does saccadic eye movement. J Vis 2010. [DOI: 10.1167/7.9.385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
92
|
Watanabe J, Maeda T, Tachi S. The time course of localization errors for repeatedly flashing stimuli through a saccade. J Vis 2010. [DOI: 10.1167/3.9.695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
93
|
Watanabe J, Tachi S. Visual persistence of saccade-induced image smear. J Vis 2010. [DOI: 10.1167/5.8.447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
94
|
|
95
|
Liu G, Iwata K, Ogasawara T, Watanabe J, Fukazawa K, Ishihara K, Asawa Y, Fujihara Y, Chung UL, Moro T, Takatori Y, Takato T, Nakamura K, Kawaguchi H, Hoshi K. Selection of highly osteogenic and chondrogenic cells from bone marrow stromal cells in biocompatible polymer-coated plates. J Biomed Mater Res A 2010; 92:1273-82. [PMID: 19330850 DOI: 10.1002/jbm.a.32460] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
To enrich the subpopulation that preserves self-renewal and multipotentiality from conventionally prepared bone marrow stromal cells (MSCs), we attempted to use 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer-coated plates that selected the MSCs with strong adhesion ability and evaluated the proliferation ability or osteogenic/chondrogenic potential of the MPC polymer-selected MSCs. The number of MSCs that were attached to the MPC polymer-coated plates decreased with an increase in the density of MPC unit (0-10%), whereas no significant difference in the proliferation ability was seen among these cells. The surface epitopes of CD29, CD44, CD105, and CD166, and not CD34 or CD45, were detectable in the cells of all MPC polymer-coated plates, implying that they belong to the MSC category. In the osteogenic and chondrogenic induction, the MSCs selected by the 2-5% MPC unit composition showed higher expression levels of osteoblastic and chondrocytic markers (COL1A1/ALP, or COL2A1/COL10A1/Sox9) at passage 2, compared with those of 0-1% or even 10% MPC unit composition, while the enhanced effects continued by passage 5. The selection based on the adequate cell adhesiveness by the MPC polymer-coated plates could improve the osteogenic and chondrogenic potential of MSCs, which would provide cell sources that can be used to treat the more severe and various bone/cartilage diseases.
Collapse
|
96
|
Aldana PH, Mendez M, Velapatiño B, Santivañez L, Balqui J, Finger S, Sherman J, Zimic M, Cabrera L, Watanabe J, Rodriguez C, Gilman R, Berg D. DNA-Level diversity and relatedness of Helicobacter pylori strains in Shantytown families in Peru and transmission in a developing-country setting. Int J Infect Dis 2010. [DOI: 10.1016/j.ijid.2010.02.1546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
97
|
Niibe Y, Watanabe J, Tsunoda S, Arai M, Arai T, Kawaguchi M, Matsuo K, Jobo T, Ono S, Numata A, Unno N, Hayakawa K. Concomitant expression of HER2 and HIF-1alpha is a predictor of poor prognosis in uterine cervical carcinoma treated with concurrent chemoradiotherapy: prospective analysis (KGROG0501). EUR J GYNAECOL ONCOL 2010; 31:491-496. [PMID: 21061787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
BACKGROUND In previously reported retrospective analyses of uterine cervical carcinoma cases, HER2 was correlated with poor radiation sensitivity and poor treatment outcomes and HIF-1alpha was found to be an indicator of poor prognosis. To date, no prospective studies have been performed to evaluate the radiation sensitivity and treatment outcomes of patients with uterine cervical carcinoma relative to HER2 and HIF-1alpha expressions. We conducted a prospective evaluation of HER2 and HIF-1alpha in cases of locally advanced uterine cervical carcinoma treated with concurrent chemoradiotherapy. METHODS Between June 2005 and April 2008, 25 patients with locally advanced uterine cervical carcinoma were registered in this study, KGROG0501. Their clinical stages were Ib2/IIb/IIIb/IVa in 1/2/22/1 cases, respectively. Nineteen cases had squamous cell carcinoma and six had adenocarcinoma. HER2 expression and HIF-1alpha expression were analyzed using an immunohistochemical kit on pretreatment biopsied specimens. HIF-1alpha expression was studied using another commercial immunohistochemical kit on pretreatment biopsied specimens. The survival rates were compared between patients with and without positive HER2 and HIF-1alpha expressions. RESULTS The 20-month survival of HER2(-) and HIF-1alpha(-) cases (n = 6) was 100% and that of HER2(+) and HIF-1alpha(+) cases (n = 4) was 37.5% (p = 0.0032). CONCLUSIONS In this first prospective analysis of patients with uterine cervical carcinoma treated with concurrent chemoradiotherapy, concomitant expression of HER2 and HIF-1alpha was suggested to be a strong indicator of poor prognosis. A novel therapy including molecular targeted therapy such as anti-HER2 and anti-HIF-1alpha may be worth considering in patients with concomitant expression of HER2 and HIF-1alpha.
Collapse
|
98
|
Toi M, Iwata H, Fujiwara Y, Ito Y, Nakamura S, Tokuda Y, Taguchi T, Rai Y, Aogi K, Arai T, Watanabe J, Wakamatsu T, Katsura K, Ellis CE, Gagnon RC, Allen KE, Sasaki Y, Takashima S. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 2009; 101:1676-82. [PMID: 19844234 PMCID: PMC2778543 DOI: 10.1038/sj.bjc.6605343] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Background: HER2-positive metastatic breast cancer (MBC) relapsing after trastuzumab-based therapy may require continued HER2 receptor inhibition to control the disease and preserve the patients' quality-of-life. Efficacy and safety of lapatinib monotherapy was evaluated in Japanese breast cancer patients after trastuzumab-based therapies. Methods: In studies, EGF100642 and EGF104911 evaluated the efficacy and safety of oral lapatinib given 1500 mg once daily in patients with advanced or MBC. All patients progressed on anthracyclines and taxanes; HER2-positive patients had also progressed on trastuzumab. Results: For HER2-positive tumours (n=100), objective response rate was 19.0% (95% confidence interval (CI): 11.8–28.1) and clinical benefit rate (CBR) was 25.0% (95% CI: 16.9–34.7). One out of 22 HER2-negative tumour was documented as complete response (n=22). The median time-to-progression (TTP) in the HER2-positive and HER2-negative groups was 13.0 and 8.0 weeks (P=0.007); median overall survival was 58.3 and 40.0 weeks, respectively. The most frequent adverse event was diarrhoea. TTP and CBR were significantly associated with HER2 expression. Patients with tumours harbouring an H1047R PIK3CA mutation or low expression of PTEN derived clinical benefit from lapatinib. Conclusion: Lapatinib monotherapy had shown anti-tumour activity in Japanese patients with HER2-positive MBC that relapsed after trastuzumab-based therapy, including those with brain metastases. Patients benefiting from lapatinib may have biomarker profiles differing from that reported for trastuzumab.
Collapse
|
99
|
Nishizawa K, Nishiyama H, Ohishi S, Saito R, Watanabe J, Fujii N, Ogawa O. MP-20.01: Fluorescent Imaging of Bladder Cancer Using T140 Analogue, A CXCR4 Antagonistic Peptide. Urology 2009. [DOI: 10.1016/j.urology.2009.07.762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
100
|
Hough LE, Spannuth M, Nakata M, Coleman DA, Jones CD, Dantlgraber G, Tschierske C, Watanabe J, Körblova E, Walba DM, Maclennan JE, Glaser MA, Clark NA. Chiral Isotropic Liquids from Achiral Molecules. Science 2009; 325:452-6. [DOI: 10.1126/science.1170028] [Citation(s) in RCA: 231] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|